[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz
Baptist
B
Medizinische Klinik IV, Otfried-Müller-Str. 10, 72076 Tübingen. baptist.gallwitz@med.uni-tuebigen.de
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D054795:Incretins / Q000502:physiology; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin
D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D009570:Nitriles; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D052216:Glucagon-Like Peptide 1; C502994:saxagliptin; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate